前收市價 | 103.79 |
開市 | 105.14 |
買盤 | 103.40 x 200 |
賣出價 | 103.49 x 200 |
今日波幅 | 102.32 - 105.14 |
52 週波幅 | 62.55 - 144.43 |
成交量 | |
平均成交量 | 3,834,985 |
市值 | 39.605B |
Beta 值 (5 年,每月) | 1.59 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -12.33 |
業績公佈日 | 2024年5月02日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 132.36 |
Brad Miller is helping Moderna shift from its reliance on COVID vaccines, with the company hoping to introduce up to 15 new drugs over a five-year period.
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ’s expansion in the cardiovascular space with the $13.1 billion acquisition of heart device firm Shockwave Medical Inc (NASDAQ: SWAV). First Quarter Highlights For the period ended in March, the healthcare company posted a revenue
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.